Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Elisabeth Schorb, Juergen Finke, Gabriele Ihorst, Benjamin Kasenda, Heidi Fricker, Gerald Illerhaus

ABSTRACT

BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising incidence among patients > 65 years. Although elderly patients are able to tolerate aggressive systemic chemotherapy, previous studies have demonstrated inferior outcomes for patients who present with a poor performance status (PS) and older age. Usually, intensive treatment approaches including high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) are only offered to patients younger than 65-70 years of age. METHODS: This is an open-label, multicentric, non-randomized, single arm phase II trial. We will recruit 51 immuno-competent patients with newly diagnosed PCNSL from 12 German centers. The objective is to investigate the efficacy of age-adapted induction treatment followed by HDT-ASCT. All enrolled patients will undergo induction chemotherapy consisting of 2 cycles of rituximab 375 mg/m2/d (days 0 & 4), methotrexate 3.5 g/m2 (d1), and cytarabine 2 × 2 g/m2/d (d2-3) every 21 days. After 2 cycles of induction chemotherapy, patients achieving at least stable disease will undergo HDT-ASCT with busulfan 3.2 mg/kg/d (days - 7-(- 6)) and thiotepa 5 mg/kg/d (days - 5-(- 4)) followed by autologous stem cell transplantation. The primary endpoint of this study is 1-year progression-free survival (PFS). Secondary endpoints include PFS, overall survival, treatment response and treatment-related morbidities. Minimal follow-up after treatment completion is 12 months. DISCUSSION: Current treatment options for PCNSL have improved over the last years, resulting in the potential to achieve durable remission or cure in patients < 70 years. Age alone may not be the only criterion to select patients for this effective treatment approach and probably many elderly patients are undertreated just because of advanced age. There have been no multicentre trials investigating this curative treatment concept in elderly and fit PCNSL patients so far. We aim to answer whether HDT-ASCT is feasible and effective in fit patients > 65 years with newly-diagnosed PCNSL. TRIAL REGISTRATION: German clinical trials registry DRKS00011932 registered 18 August 2017. More... »

PAGES

287

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5473-z

DOI

http://dx.doi.org/10.1186/s12885-019-5473-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1113086442

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30925912


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Freiburg", 
          "id": "https://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Hugstetter Stra\u00dfe 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schorb", 
        "givenName": "Elisabeth", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Freiburg", 
          "id": "https://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Hugstetter Stra\u00dfe 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finke", 
        "givenName": "Juergen", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Freiburg", 
          "id": "https://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ihorst", 
        "givenName": "Gabriele", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Basel", 
          "id": "https://www.grid.ac/institutes/grid.410567.1", 
          "name": [
            "Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany", 
            "Department of Medical Oncology & Institute of Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kasenda", 
        "givenName": "Benjamin", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Freiburg", 
          "id": "https://www.grid.ac/institutes/grid.5963.9", 
          "name": [
            "Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Hugstetter Stra\u00dfe 55, 79106, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fricker", 
        "givenName": "Heidi", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinikum Stuttgart", 
          "id": "https://www.grid.ac/institutes/grid.419842.2", 
          "name": [
            "Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Illerhaus", 
        "givenName": "Gerald", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3324/haematol.2012.076075", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001762047"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds059", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002156238"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.13.524", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003658256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2008.298", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006404715", 
          "https://doi.org/10.1038/bmt.2008.298"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00127-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007449797"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.08.2941", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010797136"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3324/haematol.11771", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013678538"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-3026(16)00036-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017818958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.14073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025226465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/bjh.14073", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025226465"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)61416-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031922698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(09)61416-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031922698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2016.334", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040189883", 
          "https://doi.org/10.1038/leu.2016.334"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.2117", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050156129"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbmt.2010.11.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050333386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.5533", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051914205"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.09.139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.6086", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e318297eeba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064357812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e318297eeba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064357812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e318297eeba", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064357812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.3.742", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074750681"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2017.23", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085050285", 
          "https://doi.org/10.1038/bmt.2017.23"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nox187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092024481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nox187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092024481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nox187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092024481"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s2352-3026(17)30174-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092273808"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising incidence among patients >\u200965\u2009years. Although elderly patients are able to tolerate aggressive systemic chemotherapy, previous studies have demonstrated inferior outcomes for patients who present with a poor performance status (PS) and older age. Usually, intensive treatment approaches including high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) are only offered to patients younger than 65-70\u2009years of age.\nMETHODS: This is an open-label, multicentric, non-randomized, single arm phase II trial. We will recruit 51 immuno-competent patients with newly diagnosed PCNSL from 12 German centers. The objective is to investigate the efficacy of age-adapted induction treatment followed by HDT-ASCT. All enrolled patients will undergo induction chemotherapy consisting of 2\u2009cycles of rituximab 375\u2009mg/m2/d (days 0 & 4), methotrexate 3.5\u2009g/m2 (d1), and cytarabine 2\u2009\u00d7\u20092 g/m2/d (d2-3) every 21\u2009days. After 2\u2009cycles of induction chemotherapy, patients achieving at least stable disease will undergo HDT-ASCT with busulfan 3.2\u2009mg/kg/d (days -\u20097-(-\u20096)) and thiotepa 5\u2009mg/kg/d (days -\u20095-(-\u20094)) followed by autologous stem cell transplantation. The primary endpoint of this study is 1-year progression-free survival (PFS). Secondary endpoints include PFS, overall survival, treatment response and treatment-related morbidities. Minimal follow-up after treatment completion is 12\u2009months.\nDISCUSSION: Current treatment options for PCNSL have improved over the last years, resulting in the potential to achieve durable remission or cure in patients <\u200970\u2009years. Age alone may not be the only criterion to select patients for this effective treatment approach and probably many elderly patients are undertreated just because of advanced age. There have been no multicentre trials investigating this curative treatment concept in elderly and fit PCNSL patients so far. We aim to answer whether HDT-ASCT is feasible and effective in fit patients >\u200965\u2009years with newly-diagnosed PCNSL.\nTRIAL REGISTRATION: German clinical trials registry DRKS00011932 registered 18 August 2017.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5473-z", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients", 
    "pagination": "287", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5473-z"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1113086442"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1bf780326d40cf5fcf036d1cc955e10306efa7921a86a44737b31ea6f5b7bf84"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30925912"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5473-z", 
      "https://app.dimensions.ai/details/publication/pub.1113086442"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-16T06:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000377_0000000377/records_106822_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-019-5473-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5473-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5473-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5473-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5473-z'


 

This table displays all metadata directly associated to this object as RDF triples.

171 TRIPLES      21 PREDICATES      50 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5473-z schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Nac309a32398946d8861c542d370d7571
4 schema:citation sg:pub.10.1038/bmt.2008.298
5 sg:pub.10.1038/bmt.2017.23
6 sg:pub.10.1038/leu.2016.334
7 https://doi.org/10.1016/j.bbmt.2010.11.011
8 https://doi.org/10.1016/s0140-6736(09)61416-1
9 https://doi.org/10.1016/s0959-8049(01)00127-7
10 https://doi.org/10.1016/s2352-3026(16)00036-3
11 https://doi.org/10.1016/s2352-3026(17)30174-6
12 https://doi.org/10.1093/annonc/mds059
13 https://doi.org/10.1093/neuonc/nox187
14 https://doi.org/10.1111/bjh.14073
15 https://doi.org/10.1200/jco.2001.19.3.742
16 https://doi.org/10.1200/jco.2003.09.139
17 https://doi.org/10.1200/jco.2005.04.6086
18 https://doi.org/10.1200/jco.2005.13.524
19 https://doi.org/10.1200/jco.2006.06.2117
20 https://doi.org/10.1200/jco.2006.08.2941
21 https://doi.org/10.1200/jco.2007.13.5533
22 https://doi.org/10.1212/wnl.0b013e318297eeba
23 https://doi.org/10.3324/haematol.11771
24 https://doi.org/10.3324/haematol.2012.076075
25 schema:datePublished 2019-12
26 schema:datePublishedReg 2019-12-01
27 schema:description BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising incidence among patients > 65 years. Although elderly patients are able to tolerate aggressive systemic chemotherapy, previous studies have demonstrated inferior outcomes for patients who present with a poor performance status (PS) and older age. Usually, intensive treatment approaches including high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) are only offered to patients younger than 65-70 years of age. METHODS: This is an open-label, multicentric, non-randomized, single arm phase II trial. We will recruit 51 immuno-competent patients with newly diagnosed PCNSL from 12 German centers. The objective is to investigate the efficacy of age-adapted induction treatment followed by HDT-ASCT. All enrolled patients will undergo induction chemotherapy consisting of 2 cycles of rituximab 375 mg/m2/d (days 0 & 4), methotrexate 3.5 g/m2 (d1), and cytarabine 2 × 2 g/m2/d (d2-3) every 21 days. After 2 cycles of induction chemotherapy, patients achieving at least stable disease will undergo HDT-ASCT with busulfan 3.2 mg/kg/d (days - 7-(- 6)) and thiotepa 5 mg/kg/d (days - 5-(- 4)) followed by autologous stem cell transplantation. The primary endpoint of this study is 1-year progression-free survival (PFS). Secondary endpoints include PFS, overall survival, treatment response and treatment-related morbidities. Minimal follow-up after treatment completion is 12 months. DISCUSSION: Current treatment options for PCNSL have improved over the last years, resulting in the potential to achieve durable remission or cure in patients < 70 years. Age alone may not be the only criterion to select patients for this effective treatment approach and probably many elderly patients are undertreated just because of advanced age. There have been no multicentre trials investigating this curative treatment concept in elderly and fit PCNSL patients so far. We aim to answer whether HDT-ASCT is feasible and effective in fit patients > 65 years with newly-diagnosed PCNSL. TRIAL REGISTRATION: German clinical trials registry DRKS00011932 registered 18 August 2017.
28 schema:genre research_article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N0bc61a6622434c418666aa11a0c0c7a0
32 N573fb45cbe11483cbc61ed50a9e3d348
33 sg:journal.1024632
34 schema:name Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients
35 schema:pagination 287
36 schema:productId N17874e91ed2442eabf54722566613fb0
37 N6af1d6aace004a2383529fdcd63a5f4b
38 N8d3c4ce85f0d4d639ba80938d71b9f30
39 Ne948c07bd8cb4a828289d82e3abc6686
40 Nedd60bce56a44424b0a72d44403d45cc
41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113086442
42 https://doi.org/10.1186/s12885-019-5473-z
43 schema:sdDatePublished 2019-04-16T06:23
44 schema:sdLicense https://scigraph.springernature.com/explorer/license/
45 schema:sdPublisher Nac6948d9c39349518f718a5bcab6cf7f
46 schema:url https://link.springer.com/10.1186%2Fs12885-019-5473-z
47 sgo:license sg:explorer/license/
48 sgo:sdDataset articles
49 rdf:type schema:ScholarlyArticle
50 N0bc61a6622434c418666aa11a0c0c7a0 schema:volumeNumber 19
51 rdf:type schema:PublicationVolume
52 N166f932ebf13491cbc51815efa10f875 rdf:first N5e1a57e22b914fa5a6b9fb5612fe2b13
53 rdf:rest Na27e0e334e444c1a98660d38a4fc53e0
54 N17874e91ed2442eabf54722566613fb0 schema:name nlm_unique_id
55 schema:value 100967800
56 rdf:type schema:PropertyValue
57 N35166fe728534f34898e59e9ff059ed9 schema:affiliation https://www.grid.ac/institutes/grid.419842.2
58 schema:familyName Illerhaus
59 schema:givenName Gerald
60 rdf:type schema:Person
61 N573fb45cbe11483cbc61ed50a9e3d348 schema:issueNumber 1
62 rdf:type schema:PublicationIssue
63 N5e1a57e22b914fa5a6b9fb5612fe2b13 schema:affiliation https://www.grid.ac/institutes/grid.5963.9
64 schema:familyName Ihorst
65 schema:givenName Gabriele
66 rdf:type schema:Person
67 N6af1d6aace004a2383529fdcd63a5f4b schema:name dimensions_id
68 schema:value pub.1113086442
69 rdf:type schema:PropertyValue
70 N7e83246ed9e14d4f8fb66d038f53e5fc schema:affiliation https://www.grid.ac/institutes/grid.5963.9
71 schema:familyName Schorb
72 schema:givenName Elisabeth
73 rdf:type schema:Person
74 N8d3c4ce85f0d4d639ba80938d71b9f30 schema:name readcube_id
75 schema:value 1bf780326d40cf5fcf036d1cc955e10306efa7921a86a44737b31ea6f5b7bf84
76 rdf:type schema:PropertyValue
77 Na27e0e334e444c1a98660d38a4fc53e0 rdf:first Nf7f51ba3d5ac4fd2b66536f7bec7cac5
78 rdf:rest Nda2c767184b04e649c16e51c03aaf4f1
79 Nac309a32398946d8861c542d370d7571 rdf:first N7e83246ed9e14d4f8fb66d038f53e5fc
80 rdf:rest Nd4c4c485ea55485e8c523bcd423fc528
81 Nac6948d9c39349518f718a5bcab6cf7f schema:name Springer Nature - SN SciGraph project
82 rdf:type schema:Organization
83 Nb58c871166da4af3adfdef7617c01fd3 rdf:first N35166fe728534f34898e59e9ff059ed9
84 rdf:rest rdf:nil
85 Nbbd6178d8d4247f3b142d10ebae59ec2 schema:affiliation https://www.grid.ac/institutes/grid.5963.9
86 schema:familyName Fricker
87 schema:givenName Heidi
88 rdf:type schema:Person
89 Nd23b2276a68e45c8ad5591c5da595e44 schema:affiliation https://www.grid.ac/institutes/grid.5963.9
90 schema:familyName Finke
91 schema:givenName Juergen
92 rdf:type schema:Person
93 Nd4c4c485ea55485e8c523bcd423fc528 rdf:first Nd23b2276a68e45c8ad5591c5da595e44
94 rdf:rest N166f932ebf13491cbc51815efa10f875
95 Nda2c767184b04e649c16e51c03aaf4f1 rdf:first Nbbd6178d8d4247f3b142d10ebae59ec2
96 rdf:rest Nb58c871166da4af3adfdef7617c01fd3
97 Ne948c07bd8cb4a828289d82e3abc6686 schema:name pubmed_id
98 schema:value 30925912
99 rdf:type schema:PropertyValue
100 Nedd60bce56a44424b0a72d44403d45cc schema:name doi
101 schema:value 10.1186/s12885-019-5473-z
102 rdf:type schema:PropertyValue
103 Nf7f51ba3d5ac4fd2b66536f7bec7cac5 schema:affiliation https://www.grid.ac/institutes/grid.410567.1
104 schema:familyName Kasenda
105 schema:givenName Benjamin
106 rdf:type schema:Person
107 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
108 schema:name Medical and Health Sciences
109 rdf:type schema:DefinedTerm
110 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
111 schema:name Oncology and Carcinogenesis
112 rdf:type schema:DefinedTerm
113 sg:journal.1024632 schema:issn 1471-2407
114 schema:name BMC Cancer
115 rdf:type schema:Periodical
116 sg:pub.10.1038/bmt.2008.298 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006404715
117 https://doi.org/10.1038/bmt.2008.298
118 rdf:type schema:CreativeWork
119 sg:pub.10.1038/bmt.2017.23 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085050285
120 https://doi.org/10.1038/bmt.2017.23
121 rdf:type schema:CreativeWork
122 sg:pub.10.1038/leu.2016.334 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040189883
123 https://doi.org/10.1038/leu.2016.334
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/j.bbmt.2010.11.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050333386
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1016/s0140-6736(09)61416-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031922698
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/s0959-8049(01)00127-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007449797
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1016/s2352-3026(16)00036-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017818958
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1016/s2352-3026(17)30174-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092273808
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1093/annonc/mds059 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002156238
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1093/neuonc/nox187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092024481
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1111/bjh.14073 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025226465
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1200/jco.2001.19.3.742 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074750681
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1200/jco.2003.09.139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203872
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1200/jco.2005.04.6086 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204226
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1200/jco.2005.13.524 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003658256
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1200/jco.2006.06.2117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050156129
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1200/jco.2006.08.2941 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010797136
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1200/jco.2007.13.5533 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051914205
154 rdf:type schema:CreativeWork
155 https://doi.org/10.1212/wnl.0b013e318297eeba schema:sameAs https://app.dimensions.ai/details/publication/pub.1064357812
156 rdf:type schema:CreativeWork
157 https://doi.org/10.3324/haematol.11771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013678538
158 rdf:type schema:CreativeWork
159 https://doi.org/10.3324/haematol.2012.076075 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001762047
160 rdf:type schema:CreativeWork
161 https://www.grid.ac/institutes/grid.410567.1 schema:alternateName University Hospital of Basel
162 schema:name Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany
163 Department of Medical Oncology & Institute of Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
164 rdf:type schema:Organization
165 https://www.grid.ac/institutes/grid.419842.2 schema:alternateName Klinikum Stuttgart
166 schema:name Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany
167 rdf:type schema:Organization
168 https://www.grid.ac/institutes/grid.5963.9 schema:alternateName University of Freiburg
169 schema:name Clinical Trials Unit, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany
170 Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Hugstetter Straße 55, 79106, Freiburg, Germany
171 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...